Munich, Germany – 26th November 2024 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Muhammad Ali Memon as its Chief Medical Officer, effective 1st January 2025.
Dr. Memon is a qualified ophthalmologist and joins CTx from AAVantgarde Bio, where he held the position of Vice President, Clinical Science and Safety. Prior to AAVantgarde, Dr. Memon has held various roles including Clinical Director at Novai as well being an honorary consultant at Moorfields Eye Hospital in London.
Dr. Memon received his medical degree from Aga Khan University, prior to his research fellowship at Harvard University. He then joined the Royal College of Ophthalmologists for his Ophthalmology Residency Program.
We are excited to welcome Ali to the CTx team as Chief Medical Officer. Ali’s extensive clinical experience and expertise in ophthalmic clinical development will be critical as we prepare to bring our lead asset CTx001, into the clinic. We are excited to have him join us in advancing our vision to develop the next generation of complement therapies.
Dr Rafiq Hasan
Chief Executive Officer
I am thrilled to join CTx in developing treatments for the underserved and rapidly growing population with age-related macular degeneration. CTx001, a single-dose gene therapy, holds the potential to reshape Geographic Atrophy treatment by targeting the complement system. Encouraging preclinical findings demonstrate substantial modulation of the complement pathway, providing hope to millions of GA patients who currently have few therapeutic options. With this novel approach, CTx001 could significantly impact the GA treatment landscape and enhance the quality of life for those living with this challenging condition.
Dr Muhammad Ali Memon
Chief Medical Officer
Company Contact
Dr Rafiq Hasan, CEO and Managing Director
Complement Therapeutics GmbH
Email: info@complementtx.com